



Frequency of *Staphylococcus pseudintermedius* in canine skin infections and antibiotic resistance profiles of the recovered isolates

İnci Başak Müştak^{1*}, Hamit Kaan Müştak², Seyyide Sarıçam³, Tuğçe Üstün⁴, Asena Esra Erdem⁵

^{1,2,3,4,5} Ankara University Faculty of Veterinary Medicine, Department of Microbiology, Ankara, Turkey

Geliş Tarihi / Received: 13.09.2020, Kabul Tarihi / Accepted: 27.10.2020

Abstract: In this study, 61 *Staphylococcus pseudintermedius* strains were isolated from 77 dogs with skin infections. Antimicrobial resistance to commonly used antibiotics was evaluated by the disc diffusion method. The presence of the *blaZ* and *mecA* genes responsible respectively for penicillin and methicillin resistance was investigated by PCR. The *S. pseudintermedius* isolates were highly resistant to tetracycline (47.5%) and penicillin (40.9%) while all isolates were susceptible to amikacin (100%). All 18 methicillin-resistant *S. pseudintermedius* (MRSP) strains were positive for the *mecA* gene while the 25 *S. pseudintermedius* strain isolates with the *blaZ* gene were also resistant to penicillin phenotypically. Of the 18 MRSP isolates, 14 *S. pseudintermedius* strains were resistant to three or more antibiotics, indicating that these strains showed multiple drug resistance (MDR). This report confirms previous findings that *S. pseudintermedius* is the most frequently isolated bacteria from dog skin infections. It can also be concluded that amikacin is a useful agent for treating *S. pseudintermedius* infections since all the *S. pseudintermedius* strains tested in this study were susceptible to amikacin.

Keywords: Dogs, methicillin resistance, *staphylococcus pseudintermedius*

Köpek deri enfeksiyonlarında *Staphylococcus pseudintermedius* sıklığı ve elde edilen izolatların antibiyotik direnç profilleri

Özet: Bu çalışmada, deri enfeksiyonu olan 77 köpekten 61 *Staphylococcus pseudintermedius* suşu izole edilmiştir. Yaygın olarak kullanılan antibiyotiklere karşı antimikrobiyal direnç, disk difüzyon yöntemi ile değerlendirildi. Penisilin ve metisilin direncinden sorumlu sırasıyla *blaZ* ve *mecA* genlerinin varlığı PCR ile araştırıldı. *S. pseudintermedius* izolatları tetrasiklin (% 47.5) ve penisiline (% 40.9) yüksek direnç gösterirken, tüm izolatlar amikasine (% 100) duyarlıydı. 18 metisiline dirençli *S. pseudintermedius* (MRSP) suşunun tümü *mecA* geni için pozitif iken *blaZ* genine sahip 25 *S. pseudintermedius* suşu izolatu da fenotipik olarak penisiline dirençliydi. 18 MRSP izolatından 14 *S. pseudintermedius* suşu, üç veya daha fazla antibiyotiğe dirençliydi, bu da bu suşların çoklu ilaç direnci (MDR) gösterdiğini ortaya koydu. Bu rapor, *S. pseudintermedius*'ün köpek deri enfeksiyonlarından en sık izole edilen bakteri olduğuna dair önceki bulguları doğrulamaktadır. Bu çalışmada test edilen tüm *S. pseudintermedius* suşları amikasine duyarlı olduğundan, amikasinin *S. pseudintermedius* enfeksiyonlarının tedavisinde yararlı bir ajan olduğu sonucuna varılabilir.

Anahtar kelimeler: Köpek, metisilin direnci, *staphylococcus pseudintermedius*

Introduction

Staphylococcus pseudintermedius is a coagulase-positive staphylococcal species described in 2005 as a distinct species from *Staphylococcus intermedius* (Devriese et al. 2005). It is classified in the *Staphylococcus intermedius* group (SIG), which comprises *S. pseudintermedius*, *S. intermedius* and *S. delphini* (Devriese et al. 2005; Sasaki et al. 2007a; Sasaki et al. 2007b).

S. pseudintermedius is an opportunistic pathogen that colonizes the skin and mucosal surfaces in cats and dogs (Devriese et al. 2005; Rubin and Chirino-Trejo 2011; Bannoehr and Guardabassi 2012). *S. pseudintermedius* also causes clinical infections, such as canine pyoderma, otitis externa, and

nosocomial infections (Ball et al. 2008; van Duijkeren et al. 2011). *S. pseudintermedius* causes more than 90% of canine pyoderma cases (Kawakami et al. 2010; Yoon et al. 2010). Although this organism is associated with skin infections in dogs, human cases have also been described, especially among dog owners after contact with them (Van Hoovels et al. 2006; Chuang et al. 2010; Stegmann et al. 2010; Savini et al. 2013; Somayaji et al. 2016). Since the first report of human transmission of this pathogen, it has been accepted as a critical public health concern (Van Hoovels et al. 2006).

Since *S. intermedius*, *S. delphini* and *S. pseudintermedius* resemble each other phenotypically, classical biochemical tests are neither reliable nor sufficient for discriminating *Staphylococcus intermedius*

Yazışma adresi / Correspondence: İnci Başak Müştak, İrfan Baştuğ Cad. Dışkapı-Ankara E-mail: incibasak@hotmail.com

ORCID IDs of the authors: ¹0000-0001-9180-5768 • ²0000-0002-3694-1959 • ³0000-0002-2386-6857 • ⁴0000-0002-1711-5520 • ⁵0000-0001-7650-7762

group (SIG) members (Sasaki et al. 2007b; Bond and Loeffler 2012). Many methods used to discriminate *S. pseudintermedius* from other SIG members, such as restriction with certain enzymes of the house-keeping *pta* gene and *nuc* gene by PCR-restriction fragment length polymorphism (RFLP), the *hsp60* gene, 16S rDNA sequences, and the matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) (El Zubeir et al. 2007; Sasaki et al. 2007b; Bannoehr et al. 2009). The sequence analysis of the RNA polymerase B (*rpoB*) gene has been used to discriminate staphylococcal species and subspecies. This method is also recommended by the Clinical and Laboratory Standards Institute (CLSI) for identifying *S. pseudintermedius* (Mellmann et al. 2006; Petti and Clinical and Laboratory Standards Institute 2008).

Antibiotic resistance is a great challenge in treating both human and animal infections worldwide (Bannoehr and Guardabassi 2012). According to the literature, *S. pseudintermedius* remains susceptible to antibiotics, although there has been a dramatic increase in resistance to methicillin since 2006 (van Duijkeren et al. 2011; Moodley et al. 2014). Detection of methicillin resistance in *S. pseudintermedius* (MRSP) by the determination of the *mecA* gene has become a "gold standard" method (Geha et al. 1994; Chambers 1997). This gene encodes a penicillin-binding protein 2a/2' (PBP2a/PBP2'), which has a lower affinity to all beta-lactam group antibiotics. It, therefore, causes resistance to all beta-lactam and beta-lactam derivative antibiotics (Felten et al. 2002; Velasco et al. 2005; Bosgelmez-Tinaz et al. 2006; Zhu et al. 2006; Perez et al. 2007).

Beside this, beta-lactam antibiotics such as penicillin have been used in staphylococcal infections in both humans and animals. Penicillin-resistant staphylococci are the most commonly isolated strains reported in dogs and cats (Fuda et al. 2005; Malik et al. 2007). Penicillin resistance in staphylococci is mainly caused by the *blaZ* gene, which is similar to the *mecA* gene. It encodes beta-lactamases and is considered to mediate methicillin resistance (Zscheck and Murray 1993; Rosato et al. 2003). Recently, there have been reports of multi-antimicrobial resistance in *S. pseudintermedius* (Bannoehr and Guardabassi 2012; De Lucia et al. 2012; Murugaiyan et al. 2014).

The present study aimed to determine the presence of MRSP strains and the multiple drug res-

sistance (MDR) profile of *S. pseudintermedius* strains isolated from skin infections of dogs.

Materials and Methods

Isolation and identification

This study used 68 staphylococcal isolates obtained from swab samples taken from 77 dogs diagnosed with skin infections in an animal hospital in Ankara University and submitted to the Department of Microbiology between 2014 and 2018. All the staphylococcal isolates were subjected to standard microbiological procedures. After incubation on blood agar containing 5-7% ovine blood at 37°C for 24h, Gram staining, catalase test, DNase test, and coagulase test were performed. Microbact™ Staph 12S system (Staphylococcal 12S Identification System, MB1561, Oxoid) was used for further phenotypic identification.

Molecular identification of *S. pseudintermedius* isolates

For this purpose, the sequence analysis of the *rpoB* gene was performed (CLSI 2018). Briefly, the total volume of 25 µl PCR mix consisted of 3 mM MgCl₂ (Thermo Fischer Scientific, USA), 0.2 mM dNTPs (10 mM dNTP mix; Thermo Fischer Scientific, USA), 0.2 µM of each primer, 2.5 µl PCR reaction buffer, 2U Taq DNA polymerase (Thermo Fischer Scientific, USA) and 2 µl template DNA. The PCR amplification conditions were as follows: 94°C for 3 min, 30 cycles of 94°C for 1 min, 58°C for 30 s, 72°C for 1 min, and 72°C for 7 min. *S. pseudintermedius* strain obtained from Dr. Ken Kikuchi (Department of Infection Control Science, Faculty of Medicine Juntendo University, Tokyo, Japan) was used as a positive control in all phenotypic and genotypic tests.

After amplification, the PCR products were purified using a QIAquick PCR purification kit (Qiagen). For the sequence analysis, BigDye Direct Cycle Sequencing Kit (Applied Biosystems) was used according to the manufacturer's instructions. Sephadex G-50 (Sigma-Aldrich) was used for purifying the amplicons while the sequence analysis was performed in an Applied Biosystems 3500 Genetic Analyzer (Applied Biosystems). CLC Main Workbench software version 7 was used for analyzing sequences. The primers used for the amplification and sequencing of the *rpoB* gene are shown in Table 1 (Drancourt et al. 2004).

Table 1. Primers used for amplification and sequencing of the *rpoB* gene.

	Primer Sequences	Product	References
31F	F 5'- GCCTTAGGACCTGGTGGTTT-3'	800 bp	Drancourt, 2004
830R	R 5'- GTTGTAACCTTCCAWGCAT-3'		

Antimicrobial Susceptibility Tests

The antimicrobial susceptibility test was performed by disc diffusion following the recommendations of CLSI. Discs known to be used in veterinary medicine worldwide were chosen and used as follows: amikacin (AK: 30 µg); amoxicillin-clavulanic acid (AMC: 30 µg); chloramphenicol (C: 30 µg); ciprofloxacin (CIP: 5 µg); erythromycin (E: 15 µg); gentamicin (GM: 10 µg); kanamycin (K: 30 µg); neomycin (N: 10 µg); penicillin (P: 10 µg); streptomycin (S: 10 µg); tetracycline (TE: 30 µg); trimethoprim-sulfamethoxazole (SXT: 5 µg). For the methicillin resistance, oxacillin (OX: 1 µg) disc was used according to CLSI guidelines.

PCR Amplification of Methicillin and Penicillin Resistance Genes

Methicillin and penicillin resistance genes were investigated by detecting the *mecA* and *blaZ* genes described by Strommenger et al. (2003) and Martineau et al. (2000), respectively. PCR amplification was performed containing 0.2 µM of each primer, 0.2 mM dNTPs (10 mM dNTP mix; Thermo Fisher Scientific, USA), 3 mM MgCl₂ (Thermo Fisher Scientific, USA), 2.5 µL PCR reaction buffer, 2U Taq DNA polymerase (Thermo Fisher Scientific; EP0402), 2 µL of DNA as a template and nuclease-free water to produce a final volume of 25 µL. PCR conditions were as follows: strand separation at 94°C for 3 min, followed by 30 cycles of 94°C for 1 min, 55°C for 1

min, 72°C for 1 min, and 7 min at 72°C for further strand extension.

Results

A total of 61 isolates from 68 staphylococcal isolates were identified as *S. pseudintermedius* by both biochemical and sequence analysis of the *rpoB* gene while 7 isolates of 68 staphylococcal isolates were identified as *Staphylococcus delphini*.

The antimicrobial susceptibility of the 61 isolates is shown in Table 2. The lowest antibiotic resistance was observed for amikacin, gentamycin, and chloramphenicol whereas the highest resistance was observed for tetracycline and penicillin. The isolates that were resistant to at least three antibiotics were considered MDR isolates. According to CLSI guidelines, 25 *S. pseudintermedius* strains showed an MDR phenotype, 18 *S. pseudintermedius* strains had an MRSP phenotype, while 14 *S. pseudintermedius* strains had both MDR and MRSP phenotypes (Table 3). Beside this, 25 *S. pseudintermedius* strains were resistant to penicillin.

The *mecA* and *blaZ* genes were also observed in 18 and 25 strains, respectively, which indicates that these isolates were *mecA*-mediated MRSP isolates (Bemis et al. 2006). In addition, all MRSP isolates showed high antibiotic resistance (77.7%), except for amikacin. All the penicillin-resistant strains except for one showed an MDR phenotype.

Table 2. Antimicrobial susceptibility of the 61 *S. pseudintermedius* isolates.

Antimicrobial agent	Number of isolates (%)		
	Susceptible	Intermediate	Resistant
Amikacin	61 (100)	0 (0)	0 (0)
Amoxicillin-clavulanic acid	39 (63.9)	0 (0)	22 (36)
Chloramphenicol	50 (81.9)	0 (0)	11 (18)
Ciprofloxacin	47 (77)	0 (0)	14 (22.9)
Erythromycin	35 (57.3)	4 (6.5)	22 (36)
Gentamicin	50 (81.9)	4 (6.5)	7 (11.4)
Kanamycin	38 (62.2)	0 (0)	23 (37.7)
Neomycin	29 (47.5)	11 (18)	21 (34.4)
Oxacillin	37 (60.6)	6 (9.8)	18 (29.5)
Penicillin	36 (59)	0 (0)	25 (40.9)
Streptomycin	39 (63.9)	0 (0)	22 (36)
Tetracycline	32 (52.4)	0 (0)	29 (47.5)
Trimethoprim-sulfamethoxazole	47 (77)	0 (0)	14 (22.9)

Table 3. Antimicrobial susceptibility of the 18 MRSP isolates.

Antimicrobial agent	Number of isolates		
	Susceptible	Intermediate	Resistant
Amikacin	18	0	0
Amoxicillin-clavulanic acid	8	0	10
Chloramphenicol	15	0	3
Ciprofloxacin	4	0	14
Erythromycin	5	0	13
Gentamicin	14	0	4
Kanamycin	4	0	14
Neomycin	7	0	11
Penicillin	4	0	14
Streptomycin	4	0	13
Tetracycline	5	0	14
Trimethoprim-sulfamethoxazole	4	0	14

Discussion

In this study, the isolation rate of *S. pseudintermedius* was high for all staphylococcal isolates. Of the 68 staphylococcal isolates, 61 were *S. pseudintermedius*, of which 25 were MDR and 18 were MRSP. On the other hand, 18 strains of the isolates were *mecA* positive while 25 were *blaZ* positive by PCR.

S. pseudintermedius was detected in 89.7% of the dogs with skin infections by *rpoB* gene sequencing. This high isolation rate was also observed in previous studies (Kawakami et al. 2010; Bannoehr and Guardabassi 2012). Onuma et al. (2012) reported *S. pseudintermedius* isolation rates of 76% in dogs with pyoderma while Saputra et al. (2017) reported 70%. Although the comparison between different studies cannot be made easily due to the differences in the geographical region, sample type, and identification methods, these results indicate that *S. pseudintermedius* is the major causative agent of canine skin infections. In Turkey, the rate of *S. pseudintermedius* based on RFLP was 82.2% in healthy dogs and 80.4% in dogs with skin infections (Sareyyupoglu et al. 2014; Findik et al. 2018). Ozturk et al. (2010) identified *Staphylococcus* species in dogs with otitis externa, skin wounds and pyoderma. Nevertheless none of them was *S. pseudintermedius*. They isolated 19.1%, 9.7%, 7.7% *S. intermedius* in dogs with otitis externa, skin wounds, and pyoderma, respectively. However, they used 16S rRNA sequencing for identifying *Staphylococcus* species, which is not recommended by CLSI for discriminating between *S. intermedius*, *S. pseudintermedius*, and *S. delphini*. Thus, they may not have been able to identify *S. pseudintermedius* within the SIG group.

Methicillin-resistant *S. pseudintermedius* has been reported in companion animals (Ruscher et al. 2010; Weese and van Duijkeren 2010). MRSP isolation rates of 2-7% have also been reported in various European countries, even in healthy dogs (De Lucia et al. 2011; Gomez-Sanz et al. 2011; Nienhoff et al. 2011). In 2019, the proportion of MRSP isolates among clinical samples was 9.3% in one Central European setting (Krapf et al. 2019). In contrast, MRSP isolation rates of 47-66% have been reported in Asian countries (Kawakami et al. 2010; Feng et al. 2012; Bardiau et al. 2013). Turkey has only limited recent data on the frequency of MRSP isolates from canine samples. The frequency of MRSP strains in this study was lower than in Asia but higher than in Europe. The rate of MRSP isolates in the present study was also lower than in a previous study in Turkey (Sareyyupoglu et al. 2014), who reported *S. pseudintermedius* frequencies of 33.3% in shelter dogs with dermatitis. In the present study, 18 isolates were MRSP (29.5%). This decrease in MRSP rates between the two studies can be explained by new regulations that strictly control and restrict antibiotic usage in animals in Turkey.

Multidrug resistance in *S. pseudintermedius* has been reported and is a major concern in Europe. In Germany, Loeffler et al. (2007) reported that 23% of *S. pseudintermedius* isolates were MDR while Findik et al. (2018) reported 13.04% MDR *S. pseudintermedius* strains isolated from healthy dogs in Turkey. In the present study, the MDR *S. pseudintermedius* isolation rate was 40.9% in dogs with skin infections whereas Findik et al. (2018) found no MDR-MRSP isolates in healthy dogs. Menandro et al. (2019) re-

ported that all MRSP isolates (31.6%) in their study were MDR in dogs with pyoderma, conjunctivitis, otitis, or urinary tract or bone infections. In the present study, we detected 22.9% MDR-MRSP. This high level of MDR in MRSP isolates indicates that MRSP isolates usually have an MDR profile. The difference in MDR and MDR-MRSP rates may be due to differences in the animals' health condition. Finally, the identification of isolates only susceptible to amikacin reflects the limited use of amikacin in veterinary practice.

In conclusion, the high frequency of MRSP isolates in dogs in Turkey constitutes a risk for public health. However, restricting the usage of antibiotics decreases antibiotic resistance in *S. pseudintermedius* strains. Comprehensive monitoring is needed to understand the epidemiology of this pathogen and the current status of antibiotic resistance in other Staphylococci.

Conflict of interest

Declaration of interest: N/A

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- Ball KR, Rubin JE, Chirino-Trejo M, Dowling PM. (2008) Antimicrobial resistance and prevalence of canine uropathogens at the Western College of Veterinary Medicine Veterinary Teaching Hospital, 2002-2007. *Can Vet J.* 49(10), 985-990.
- Bannoehr J, Franco A, Iurescia M, Battisti A, Fitzgerald JR. (2009) Molecular diagnostic identification of *Staphylococcus pseudintermedius*. *J Clin Microbiol.* 47(2), 469-471.
- Bannoehr J, Guardabassi L. (2012) *Staphylococcus pseudintermedius* in the dog: taxonomy, diagnostics, ecology, epidemiology and pathogenicity. *Vet Dermatol.* 23(4), 253-E252.
- Bardiau M, Yamazaki K, Ote I, Misawa N, Mainil JG. (2013) Characterization of methicillin-resistant *Staphylococcus pseudintermedius* isolated from dogs and cats. *Microbiol Immunol.* 57(7), 496-501.
- Bemis DA, Jones RD, Hiatt LE, Ofori ED, Rohrbach BW, Frank LA, Kania SA. (2006) Comparison of tests to detect oxacillin resistance in *Staphylococcus intermedius*, *Staphylococcus schleiferi*, and *Staphylococcus aureus* isolates from canine hosts. *J Clin Microbiol.* 44(9), 3374-3376.
- Bond R, Loeffler A. (2012) What's happened to *Staphylococcus intermedius*? Taxonomic revision and emergence of multi-drug resistance. *J Small Anim Pract.* 53(3), 147-154.
- Bosgelmez-Tinaz G, Ulusoy S, Aridogan B, Coskun-Ari F. (2006) Evaluation of different methods to detect oxacillin resistance in *Staphylococcus aureus* and their clinical laboratory utility. *Eur J Clin Microbiol Infect Dis.* 25(6), 410-412.
- Chambers HF. (1997) Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. *Clin Microbiol Rev.* 10(4), 781-791.
- Chuang CY, Yang YL, Hsueh PR, Lee PI. (2010) Catheter-Related Bacteremia Caused by *Staphylococcus pseudintermedius* Refractory to Antibiotic-Lock Therapy in a Hemophilic Child with Dog Exposure. *J Clin Microbiol.* 48(4), 1497-1498.
- CLSI. (2018) Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing; Approved Guideline. In: Institute CaLS, ed. *CLSI document MM18-A*. Wayne, PA ABD.
- CLSI. (2019) Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. *CLSI supplement M100*. Wayne, PA ABD.
- De Lucia M, Moodley A, Latronico F, Giordano A, Caldin M, Fondati A, Guardabassi L. (2011) Prevalence of canine methicillin resistant *Staphylococcus pseudintermedius* in a veterinary diagnostic laboratory in Italy. *Res Vet Sci.* 91(3), 346-348.
- Devriese LA, Vancanneyt M, Baele M, Vaneechoutte M, De Graef E, Snaauwaert C, Cleenwerck I, Dawyndt P, Swings J, Decostere A, Haesebrouck F. (2005) *Staphylococcus pseudintermedius* sp. nov., a coagulase-positive species from animals. *Int J Syst Evol Microbiol.* 55(4), 1569-1573.
- Drancourt M, Roux V, Fournier PE, Raoult D. (2004) rpoB gene sequence-based identification of aerobic Gram-positive cocci of the genera *Streptococcus*, *Enterococcus*, *Gemella*, *Abiotrophia*, and *Granulicatella*. *J Clin Microbiol.* 42(2), 497-504.
- El Zubeir IEM, Kanbar T, Alber J, Lammler C, Akineden O, Weiss R, Zschock M. (2007) Phenotypic and genotypic characteristics of methicillin/oxacillin-resistant *Staphylococcus intermedius* isolated from clinical specimens during routine veterinary microbiological examinations. *Vet Microbiol.* 121(1-2), 170-176.
- Felten A, Grandry B, Lagrange PH, Casin I. (2002) Evaluation of three techniques for detection of low-level methicillin-resistant *Staphylococcus aureus* (MRSA): a disk diffusion method with cefoxitin and moxalactam, the Vitek 2 system, and the MRSA-screen latex agglutination test. *J Clin Microbiol.* 40(8), 2766-2771.
- Feng YY, Tian W, Lin DC, Luo QY, Zhou YZ, Yang T, Deng YT, Liu YH, Liu JH. (2012) Prevalence and characterization of methicillin-resistant *Staphylococcus pseudintermedius* in pets from South China. *Vet Microbiol.* 160(3-4), 517-524.
- Findik A, Ciftci A, Onyay T, Sezener MG, Kocak Y, Gulhan T. (2018) Determination of methicillin resistance and some genotypic characteristics of staphylococci isolated from dogs and their owners. *Turk J Vet Anim Sci.* 42(6), 549-555.
- Fuda CC, Fisher JF, Mobashery S. (2005) Beta-lactam resistance in *Staphylococcus aureus*: the adaptive resistance of a plastic genome. *Cell Mol Life Sci.* 62(22), 2617-2633.
- Geha DJ, Uhl JR, Gustaferro CA, Persing DH. (1994) Multiplex PCR for identification of methicillin-resistant staphylococci in the clinical laboratory. *J Clin Microbiol.* 32(7), 1768-1772.
- Gomez-Sanz E, Torres C, Lozano C, Saenz Y, Zarazaga M. (2011) Detection and characterization of methicillin-resistant *Staphylococcus pseudintermedius* in healthy dogs in La Rioja, Spain. *Comp Immunol Microbiol Infect Dis.* 34(5), 447-453.
- Kawakami T, Shibata S, Murayama N, Nagata M, Nishifuji K, Iwasaki T, Fukata T. (2010) Antimicrobial Susceptibility and Methicillin Resistance in *Staphylococcus pseudintermedius* and *Staphylococcus schleiferi* subsp. *coagulans* Isolated from Dogs with Pyoderma in Japan. *J Vet Med Sci.* 72(12), 1615-1619.
- Krapf M, Muller E, Reissig A, Slickers P, Braun SD, Muller E, Ehrlich R, Monecke S. (2019) Molecular characterisation of methicillin-resistant *Staphylococcus pseudintermedius* from dogs

- and the description of their SCCmec elements. *Vet Microbiol.* 233, 196-203.
- Malik S, Christensen H, Peng H, Barton MD. (2007) Presence and diversity of the beta-lactamase gene in cat and dog staphylococci. *Vet Microbiol.* 123(1-3), 162-168.
- Martineau F, Picard FJ, Grenier L, Roy PH, Ouellette M, Bergeron MG. (2000) Multiplex PCR assays for the detection of clinically relevant antibiotic resistance genes in staphylococci isolated from patients infected after cardiac surgery. The ESPRIT Trial. *J Antimicrob Chemother.* 46(4), 527-534.
- Mellmann A, Becker K, Von Eiff C, Keckevoet U, Schumann P, Harmsen D. (2006) Sequencing and staphylococci identification. *Emerg Infect Dis.* 12(2), 333-336.
- Moodley A, Damborg P, Nielsen SS. (2014) Antimicrobial resistance in methicillin susceptible and methicillin resistant *Staphylococcus pseudintermedius* of canine origin: Literature review from 1980 to 2013. *Vet Microbiol.* 171(3-4), 337-341.
- Murugaiyan J, Wlther B, Stamm I, Abou-Elnaga Y, Brueggemann-Schwarze S, Vincze S, Wieler LH, . Lübke-Becker A, Semmler T, Roesler U. (2014) Species differentiation within the *Staphylococcus intermedius* group using a refined MALDI-TOF MS database. *Clin Microbiol Infect.* 20, 1007-1015.
- Nienhoff U, Kadlec K, Chaberny IF, Verspohl J, Gerlach GF, Kreienbrock L, Schwarz S, Simon D, Nolte I. (2011) Methicillin-resistant *Staphylococcus pseudintermedius* among dogs admitted to a small animal hospital. *Vet Microbiol.* 150(1-2), 191-197.
- Ozturk D, Avki S, Turutoglu H, Yigitarslan K, Sagnak S. (2010) Methicillin Resistance Among Coagulase-positive Staphylococci Isolated from Dogs with Otitis Externa, Skin Wounds and Pyoderma. *Kafkas Uni Vet Fak Derg.* 16(4), 651-656.
- Onuma K, Tanabe T, Sato H. (2012) Antimicrobial resistance of *Staphylococcus pseudintermedius* isolates from healthy dogs and dogs affected with pyoderma in Japan. *Vet Dermatol.* 23, 17-22, e15.
- Perez LR, Antunes AL, Barth AL, D'azevedo PA. (2007) Variations of agar screen tests for detection of methicillin resistance in staphylococci: focus on cefoxitin. *Eur J Clin Microbiol Infect Dis.* 26(4), 267-270.
- Petti CA, Clinical and Laboratory Standards Institute. (2008) *Interpretive criteria for identification of bacteria and fungi by DNA target sequencing : approved guideline*, Wayne, PA: Clinical and Laboratory Standards Institute.
- Rosato AE, Kreiswirth BN, Craig WA, Eisner W, Climo MW, Archer GL. (2003) *mecA-blaZ* corepressors in clinical *Staphylococcus aureus* isolates. *Antimicrob Agents and Chemother.* 47(4), 1460-1463.
- Rubin JE, Chirino-Trejo M. (2011) Prevalence, sites of colonization, and antimicrobial resistance among *Staphylococcus pseudintermedius* isolated from healthy dogs in Saskatoon, Canada. *J Vet Diagn Invest.* 23(2), 351-354.
- Ruscher C, Lübke-Becker A, Semmler T, Wleklinski CG, Paasch A, Soba A, Stamm I, Kopp P, Wieler LH, Walther B. (2010) Widespread rapid emergence of a distinct methicillin- and multidrug-resistant *Staphylococcus pseudintermedius* (MRSP) genetic lineage in Europe. *Vet Microbiol.* 144(3-4), 340-346.
- Saputra S, Jordan D, Worthing KA, Norris JM, Wong HS, Abraham R, Trott DJ, Abraham S. (2017) Antimicrobial resistance in coagulase-positive staphylococci isolated from companion animals in Australia: A one year study. *Plos One.* 12(4), e0176379.
- Sareyyupoglu B, Mustak HK, Cantekin Z, Diker KS. (2014) Methicillin Resistance in *Staphylococcus pseudintermedius* Isolated from Shelter Dogs in Turkey. *Kafkas Univ Vet Fak Derg.* 20(3), 435-438.
- Sasaki T, Kikuchi K, Tanaka Y, Takahashi N, Kamata S, Hiramatsu K. (2007a) Methicillin-resistant *Staphylococcus pseudintermedius* in a veterinary teaching hospital. *J Clin Microbiol.* 45(4), 1118-1125.
- Sasaki T, Kikuchi K, Tanaka Y, Takahashi N, Kamata S, Hiramatsu K. (2007b) Reclassification of phenotypically identified *Staphylococcus intermedius* strains. *J Clin Microbiol.* 45(9), 2770-2778.
- Savini V, Barbarini D, Polakowska K, Gherardi G, Bialecka A, Kasprowicz A, Polilli E, Marrollo R, Di Bonaventura G, Fazii P, D'antonio D, Miedzobrodzki J, Carretto E. (2013) Methicillin-Resistant *Staphylococcus pseudintermedius* Infection in a Bone Marrow Transplant Recipient. *J Clin Microbiol.* 51(5), 1636-1638.
- Somayaji R, Priyantha MAR, Rubin JE, Church D. (2016) Human infections due to *Staphylococcus pseudintermedius*, an emerging zoonosis of canine origin: report of 24 cases. *Diagn Microb and Infect Dis.* 85(4), 471-476.
- Stegmann R, Burnens A, Maranta CA, Perreten V. (2010) Human infection associated with methicillin-resistant *Staphylococcus pseudintermedius* ST71. *J Antimicrob Chemot.* 65(9), 2047-2048.
- Strommenger B, Kettlitz C, Werner G, Witte W. (2003) Multiplex PCR assay for simultaneous detection of nine clinically relevant antibiotic resistance genes in *Staphylococcus aureus*. *J Clin Microbiol.* 41(9), 4089-4094.
- Van Duijkeren E, Catry B, Greko C, Moreno MA, Pomba MC, Pyoralá S, Ruzauskas M, Sanders P, Threlfall EJ, Torren-Edo J, Torneke K, Antimicrobials SAG. (2011) Review on methicillin-resistant *Staphylococcus pseudintermedius*. *J Antimicrob Chemot.* 66(12), 2705-2714.
- Van Hoovels L, Vankeerberghen A, Boel A, Van Vaerenbergh K, De Beenhouwer H. (2006) First case of *Staphylococcus pseudintermedius* infection in a human. *J Clin Microbiol.* 44(12), 4609-4612.
- Velasco D, Del Mar Tomas M, Cartelle M, Beceiro A, Perez A, Molina F, Moure R, Villanueva R, Bou G. (2005) Evaluation of different methods for detecting methicillin (oxacillin) resistance in *Staphylococcus aureus*. *J Antimicrob Chemot.* 55(3), 379-382.
- Weese JS, Van Duijkeren E. (2010) Methicillin-resistant *Staphylococcus aureus* and *Staphylococcus pseudintermedius* in veterinary medicine. *Vet Microbiol.* 140(3-4), 418-429.
- Yoon JW, Lee KJ, Lee SY, Chae MJ, Park JK, Yoo JH, Park HM. (2010) Antibiotic resistance profiles of *Staphylococcus pseudintermedius* isolates from canine patients in Korea. *J Microbiol Biotechnol.* 20(12), 1764-1768.
- Zhu LX, Zhang ZW, Wang C, Yang HW, Zhang Q, Cheng J. (2006) Evaluation of the CLSI cefoxitin 30-microg disk-diffusion method for detecting methicillin resistance in staphylococci. *Clin Microbiol Infect.* 12(10), 1039-1042.
- Zscheck KK, Murray BE. (1993) Genes Involved in the Regulation of Beta-Lactamase Production in Enterococci and Staphylococci. *Antimicrob Agents Chemother.* 37(9), 1966-1970.